Rohan Palekar is the Chief Executive Officer and a member of the Board of Directors of 89bio, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases. Under his stewardship as CEO since the company’s formation in 2018, the company has grown significantly from pre-clinical stage to multiple Phase 3 programs. Rohan is a seasoned C-suite executive with over 30 years of experience in the biopharmaceutical industry. Previously, Rohan was the president and CEO of Avanir Pharmaceuticals after serving as its Chief Operations Officer and Chief Commercial Officer (CCO). As part of the senior leadership team, he led the organization through a dynamic growth phase culminating in an acquisition by Otsuka Pharmaceuticals in 2015. Prior to Avanir, Rohan served as the CCO of Medivation, where he oversaw commercial, medical affairs, CMC & manufacturing, and public relations. Earlier in his career, Rohan spent 16 years at Johnson & Johnson in various senior commercial and strategic management roles, including worldwide VP of immunology and VP of sales and marketing at Centocor. Rohan serves on the board of Neurogene Inc. (Nasdaq: NGNE) and previously served on the board of Neoluekin Therapeutics, Inc. Rohan holds an MBA from the Amos Tuck School of Business Administration at Dartmouth College and a B.Com. in Accounting and his L.L.B. in Law from the University of Mumbai. Mr. Palekar is also a certified Chartered Accountant and a Cost and Management Accountant.